Investigational drug · Phase 3
HSK39004 Dry
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD).
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "HSK39004 Dry"
First trial start
2025
Apr 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK39004 Dry", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Lung Disease (COLD)
- COPD (Chronic Obstructive Pulmonary Disease)
- Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK39004 Dry" as an intervention, largest first.
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPDPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07583849 · 376 participants (planned) · Start May 24, 2026 · Primary completion Sep 30, 2027
Drug: HSK39004 Dry Powder Inhaler Simulant; HSK39004 Dry Powder Inhaler-0.75mg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Beijing, China
- Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPDNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07425210 · 300 participants (planned) · Start Mar 2026 · Primary completion Jul 2027
Drug: HSK39004 Dry Powder Inhaler -0.75mg BID · For: Chronic Obstructive Lung Disease (COLD)
Sites: Guiyang, China
- Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingActive, not recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07108699 · 180 participants (planned) · Start Aug 13, 2025 · Primary completion Aug 30, 2026
Drug: HSK39004 Dry Powder Inhaler-0.75mg; HSK39004 Dry Powder Inhaler-1.5mg and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chengdu, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07140328 · 50 participants (planned) · Start Apr 24, 2025 · Primary completion Jul 10, 2025
Drug: HSK39004 Dry Powder Inhaler -0.75mg BID; HSK39004 Dry Powder Inhaler -1.5mg BID and 2 more · For: Chronic Obstructive Lung Disease (COLD)
Sites: Nanchang, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06971198 · 26 participants · Start Feb 10, 2025 · Primary completion Mar 28, 2025
Drug: HSK39004; Placebo · For: Healthy Volunteers
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.